Abionic bags $21M to trial rapid test of sepsis risk

Abionic has raised US$21 million to trial a test designed to give physicians rapid insights into patients that are at risk of sepsis. The test builds on Abionic’s work to develop an immunoassay platform that delivers results faster than the traditional laboratory-based process.

“We have the capacity to run most of the immunoassays that are today realized in laboratories in between two and three hours … on our platform in less than five minutes from a drop of a blood, instead of several milliliters of blood,” founder Nicolas Durand said.

Abionic has run several clinical studies of the platform in its first chosen field, allergy test; and has yielded commercial tests.

Categories: diagnostics, POC
Tags: sepsis, allergy

Published on by Winnie So. Source.